Changchun Boke Bio adult DTP vaccine approved for clinical trials

Changchun High & New Technology Industry Group announced that its subsidiary, Changchun Boke Biotechnology Co., Ltd. (Boke Bio), has received approval from the National Medical Products Administration for the clinical trial application of its adsorbed acellular diphtheria, tetanus, and pertussis combined vaccine for adults and adolescents. The approval, dated November 11, 2025, allows for the initiation of clinical trials to prevent pertussis, diphtheria, and tetanus.

The vaccine, designated for individuals aged 10 years and older, is designed to stimulate an immune response against invasive infections caused by pertussis, diphtheria, and tetanus. The company highlights that this vaccine breaks from traditional purification processes by containing inactivated pertussis toxin, filamentous hemagglutinin, diphtheria toxoid, and tetanus toxoid, complemented by an aluminum-CpG adjuvant system to evoke an immune response.

This development aims to address the rising incidence of pertussis in adolescents and adults, providing a potentially new option for vaccination in China, where current immunization schedules primarily target infants. The company anticipates that successful clinical trials and subsequent market approval will enhance its vaccine product portfolio and contribute to business growth.